Traditional drug development models are widely perceived as inefficient and lacking innovation, with the R&D costs continuing to grow even as approval of new drugs stays constant. Reflecting this reality, alternative R&D models are emerging that provide choices, including greater flexibility in funding options, asset-centric approaches, virtual drug development, improved collaboration and operational support that can propel high-potential ventures forward with de-risked assets and shorter timelines.
This panel represents similar yet distinct development models and will present different perspectives that offer support to entrepreneurs’ unique business and research needs for early-stage innovation.

Ability Level: All

Session ID: 20984